India Pesticides Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/vlkwfswuh9rru62wrukw792v.pdf

Key Takeaways


Volume & Revenue Growth

S.P. Gupta: "Our volume has increased by 26% this quarter."

Margins: The Price-Led Squeeze

S.P. Gupta: "Those margins were achieved in 2021 and 2022, they are being rationalized. The margins exceeding 25% cannot be sustainable seeing the current situation."

Capacity & Operations

D.K. Jain: "Our present capacity utilization is 66% of technical and more than 100% of formulation. If we combine together the overall capacity, it is almost about 80%."

Export & Domestic Demand

S.P. Gupta: "It will be definitely far better than FY24 numbers. Second half will be far better. Since last year export has declined very, very sharply. So now we are seeing in the international market, volumes are picking up."

Strategic Initiatives

Anand Swarup Agarwal: "By substituting imports with domestic manufacturing, we are not only enhancing our self-reliance but also contributing to the nation's economic growth."

Balance Sheet & Capital Allocation


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth15–20% YoY, mostly volume-led; above that if 3–4% price increase materializesFY25
EBITDA margin recovery18–20% from Q3 onwardQ3 FY25 onward
Capex₹110 crores, funded from internal accrualsFY25
Hamirpur technical plant commissioningTwo molecules; plants expected to commissionLast quarter FY25
Formulation capacity expansionIncreased capacity commissionedWithin this month or next month
Revenue growth (FY26)15–20% YoYFY26
EBITDA margin (FY26)18–20%FY26
Cash positionRemain cash surplusNext 1–2 years

Key Metrics

MetricQ1 FY25
Revenue₹224 cr, +9% YoY and +72% QoQ
EBITDA₹32 cr, 15% margin vs 13% in Q1 FY24
EBITDA margin14.2%, improved 149 bps YoY and 854 bps QoQ
Net profit₹19 cr, +25% YoY
Domestic revenue₹143 cr
International revenue₹77 cr
Technical sales₹142 cr vs ₹158 cr in Q1 FY24
Formulation sales₹78 cr vs ₹43 cr in Q1 FY24
Volume growth26% YoY
Revenue from new molecules~₹40 cr, 18-19% of revenue
Technical capacity utilization66%
Formulation capacity utilization>100%, using some technical facilities
Overall capacity utilization~80%
FY25 capex plan₹110 cr, combining IPL (₹50 cr) and SSL (₹65 cr)
Cash in hand₹140 cr